Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Individuals with attention-deficit hyperactivity disorder (ADHD) are likely to exhibit suicidal behaviour, and this probability is further increased in the presence of comorbid psychiatric disorders, a recent study suggests.
An 8-week attention training programme using brain-computer interface (BCI) can help improve inattentive symptoms in children with attention deficit hyperactivity disorder (ADHD), thus providing a potential nonpharmacologic option for treating ADHD, a local study finds.
A novel device for trigeminal nerve stimulation (TNS) effectively improves attention deficit hyperactivity disorder (ADHD) symptoms in children aged 8–12 years, providing a safe nonmedication approach to treating ADHD, a recent study shows.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Preschoolers are likely to follow an unhealthy dietary pattern, and patterns high in processed food and snacks contribute to an increased risk of attention-deficit/hyperactivity disorder (ADHD), whereas a pattern high in vegetables exerts a protective effect, according to a study from China.
Individuals with attention-deficit hyperactivity disorder (ADHD) who are treated with atomoxetine or methylphenidate may have a risk for elevated heart rate and systolic blood pressure (BP), according to a meta-analysis.
Individuals with attention deficiency hyperactivity disorder (ADHD) or anxiety are at greater risk of developing bipolar disorder, according to a study. Moreover, the risk further increases in those who have received diagnoses of both ADHD and anxiety.
A substantial number of patients with gambling addiction screen positive for attention-deficit/hyperactivity disorder (ADHD), according to a Singapore study. Furthermore, these patients have lower levels of gambling-related cognitions, suggesting that their gambling behaviour is rather guided by impulsivity.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.